Austin, TX (PRWEB) July 14, 2014
A status conference will be held on July 15, 2014 in the Philadelphia Court of Common Pleas for legal parties to discuss the next steps in Risperdal litigation, reports Hissey Kientz, LLP. Plaintiffs filing lawsuits against Janssen Pharmaceuticals and parent company Johnson & Johnson allege that the manufacturers failed to properly warn Risperdal users about the increased risk of developing gynecomastia. (Risperdal Litigation, case number 100300296)
According to the National Center for Biotechnology Information, gynecomastia is the benign enlargement of breast tissue in males. Gynecomastia side effects include swollen breast gland tissue, breast tenderness and nipple discharge in one or both breasts. Approximately 10%-25% of gynecomastia cases are estimated to result from the use of medications.*
Court records indicate that over 500 Risperdal lawsuits have been filed in a Mass Tort litigation underway in Pennsylvania's Philadelphia Court of Common Pleas. Many of the lawsuits allege that the use of Risperdal led to gynecomastia in male adolescents and children. (Risperdal Litigation, case number 100300296)
A 2006 study published in the Journal of Clinical Psychopharmacology reported that adolescents who took Risperdal exhibited significantly high levels of prolactin. Prolactin is a hormone that stimulates milk production and breast development and can lead to gynecomastia.**
Patients who have experienced gynecomastia after using Risperdal may wish to speak with a lawyer to find out if they are eligible to file a lawsuit. For more information about whether you may have a case, contact the attorneys at Hissey Kientz, LLP by calling toll-free at 1-866-275-4454, or by email at info(at)hkllp(dot)com.
About Hissey Kientz, LLP
Hissey Kientz, LLP (http://www.hkllp.com) represents individuals allegedly experiencing breast growth from Risperdal, as well as victims of mesothelioma and other asbestos-related diseases, birth defects linked to the antidepressant drugs Zoloft, Lexapro, Celexa and Effexor, problems with transvaginal mesh, Stryker, DePuy, and Biomet hip replacements, GranuFlo acid concentrates, Mirena IUDs and other defective drugs and medical devices.